Trials / Withdrawn
WithdrawnNCT00000809
Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID) · NIH
- Sex
- All
- Age
- 1 Day – 3 Days
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Aluminum hydroxide | |
| BIOLOGICAL | QS-21 | |
| BIOLOGICAL | MN rsgp120/HIV-1 |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2021-10-29
Source: ClinicalTrials.gov record NCT00000809. Inclusion in this directory is not an endorsement.